This was never going to happen at a premium that line of thinking or questioning has to stop imo (particularly for a biotech seeking production for a not yet proven or FDA approved product). Negotiation is a two way street... and a 7% discount is actually quite substantial imo. The blaster will be well positioned for successor or failure at the behest of recent investors in the short term...
This was never going to happen at a premium that line of...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
0.255(16.7%) |
Mkt cap ! $2.032B | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.83 | $1.71 | $27.76M | 15.59M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30000 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 48074 | 4 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |